Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
. J Immunol 1996;157:4230-8.
Wilke, "Micron-scale phase segregation in lipid monolayers induced by myelin basic protein
in the presence of a cholesterol analog," Biochimica et Biophysica Acta (BBA)--Biomembranes, vol.
Cell Protein Function Neuron Neurofilament (NF) Neuronal intermediate Triplet * filaments (IF) NF-L (light; NF-68) Mechanical stability of soma, dendrites, and axon NF-M (medium; NF-160) Mechanical stability of soma, dendrites, and axon NF-H (heavy; NF-200) Together with NF-L and NF-M, mechanical stability of the axon Astrocyte Glial fibrillary IF of mature acidic protein astrocytes (GFAP) biomarker of reactive gliosis Vimentin IF transiently expressed during development Myelinating Myelin basic protein
Compaction protein of cells (MBP) myelin in CNS and PNS Oligodendroglia Myelin CNS myelin oligodendrocyte protein (MOG) Schwann Cell Peripheral myelin PNS myelin protein-22 (PMP-22) * Individual proteins differ in their immunogenicity.
Sela, "Binding of copolymer 1 and myelin basic protein
leads to clustering of class II MHC molecules on antigen-presenting cells," International Immunology, vol.
Nielsen, "T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein
and disease activity in multiple sclerosis," Immunology, vol.
Myelin basic protein
immunoreactivity in the internal capsule of neoantes from rats on a low iodine intake or methylmercaptoimidiazole (MMI).
For the vaccine, researchers at Stanford University and Bayhill Therapeutics in Palo Alto, Calif., designed a DNA ring that encodes a slightly altered version of myelin basic protein
. The changes replaced immune-stimulating parts of the protein with immune-suppressing ones.
MBP8298: A synthetic myelin basic protein
fragment, or peptide, may make the immune system of people with MS tolerant of myelin.
The proposed mechanism of action of MBP8298 is, by design, to re-introduce such a state of "tolerance" to a critical portion of the nerve's Myelin Basic Protein
that is an immunological site of attack in many MS patients.
People with secondary progressive multiple sclerosis are currently being enrolled in a phase II/III trial outside of the United States that will evaluate the impact of an intravenously administered synthetic peptide that targets a portion of myelin basic protein
related to disease progression, according to the manufacturer, BioMS Medical Corp.
The [T.sub.H]1 cells of MS patients are biased toward myelin basic protein
(MBP) and proteolipid protein reactive cells .
Included are compositionally prominent (20%-50% of protein mass) myelin basic protein
(MBP), protein zero ([P.sub.0]), and proteolipid protein (PLP) and "myelin-related" 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP), peripheral myelin protein 22 (PMP22), myelin and lymphocyte protein (MAL), and plasmolipin.